Progressive Supranuclear Palsy Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Rasagiline in Subjects With Progressive Supranuclear Palsy (Phase III)
The purpose of this study is to determine whether rasagiline is effective in the treatment of Progressive Supranuclear Palsy (PSP), a rapidly progressing disease with a symptomatology similar to Parkinson's Disease. The major aim of this study is the limitation or halting of the process of neurodegeneration and influence postural instability.
Progressive Supranuclear Palsy (PSP) is a rapidly progressing disease with a median survival after onset of symptoms of 5.8 years.PSP is characterized by early falls, vertical ophthalmoparesis, akinetic-rigid features, prominent bulbar dysfunction and fronto-subcortical dementia. So far there is no treatment for the disease as the negative outcomes of the vast majority of studies make it impossible to set standards. As the majority of patients experience severe falls and vertigo already in the early phase of the disease, the drug of desire would be able to slow disease progression with a special focus on postural instability and exert neuroprotective effects. The monoamino oxidase inhibitor Rasagiline might be able to influence progression of PSP. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04096651 -
Pathophysiology of Gait and Posture in Progressive Supranuclear Palsy
|
N/A | |
| Recruiting |
NCT02194816 -
Modifiable Variables in Parkinsonism (MVP)
|
||
| Completed |
NCT00703677 -
A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration
|
Phase 1/Phase 2 | |
| Completed |
NCT00382824 -
Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)
|
N/A | |
| Completed |
NCT04184063 -
Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)
|
Phase 2 | |
| Recruiting |
NCT04706234 -
Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies
|
||
| Recruiting |
NCT04472130 -
Neurodegenerative Diseases Registry
|
||
| Recruiting |
NCT04139551 -
Oxford Study of Quantification in Parkinsonism
|
||
| Completed |
NCT02734485 -
Deep TMS for the Treatment of Patients With Parkinson's Disease and Progressive Supranuclear Palsy
|
N/A | |
| Completed |
NCT01110720 -
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
|
Phase 2/Phase 3 | |
| Completed |
NCT01174771 -
Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration
|
N/A | |
| Completed |
NCT00465790 -
Research of Biomarkers in Parkinson Disease
|
Phase 0 | |
| Completed |
NCT02460094 -
Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy
|
Phase 1 | |
| Active, not recruiting |
NCT04993768 -
A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)
|
Phase 2 | |
| Recruiting |
NCT03225144 -
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
|
||
| Completed |
NCT03058965 -
Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
|
Early Phase 1 | |
| Recruiting |
NCT02605785 -
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
|
N/A | |
| Completed |
NCT01353183 -
Analysis of the Enteric Nervous System Using Colonic Biopsies
|
N/A | |
| Completed |
NCT00385710 -
Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine)
|
Phase 2 | |
| Recruiting |
NCT05260151 -
Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases
|